Sanvito, Francesco http://orcid.org/0000-0003-3379-9958
Raymond, Catalina
Cho, Nicholas S.
Yao, Jingwen
Hagiwara, Akifumi
Orpilla, Joey
Liau, Linda M.
Everson, Richard G.
Nghiemphu, Phioanh L.
Lai, Albert
Prins, Robert
Salamon, Noriko
Cloughesy, Timothy F.
Ellingson, Benjamin M. http://orcid.org/0000-0002-2764-6640
Funding for this research was provided by:
U.S. Department of Defense (DoD CA20029)
Foundation for the National Institutes of Health (NIH NCI P50CA211015, NIH NCI R01CA279984, NIH NCI R01CA270027, NIH NIGMS T32 GM008042)
Article History
Received: 13 April 2023
Revised: 5 July 2023
Accepted: 27 July 2023
First Online: 26 October 2023
Declarations
:
: The scientific guarantor of this publication is Benjamin M Ellingson, University of California Los Angeles.
: Disclosures relevant to the topic of the manuscript:BME owns the patent for dynamic SAGE-EPI (patent: US 11,378,638 B2).The authors of this manuscript declare relationships with the following companies (not relevant to the topic of the manuscript):JO is currently employed by Rampart Bioscience. TFC is a cofounder, major stock holder, consultant, and board member of Katmai Pharmaceuticals, is a member of the board for the 501c3 Global Coalition for Adaptive Research, holds stock option of Notable Labs, holds stock in Chimerix, receives milestone payments and possible future royalties, is a member of the scientific advisory board for Break Through Cancer, is a member of the scientific advisory board for Cure Brain Cancer Foundation, has provided paid consulting services to GCAR; Gan & Lee; BrainStorm; Katmai; Sapience; Inovio; Vigeo Therapeutics; DNATrix; Tyme; SDP; Novartis; Roche; Kintara; Bayer; Merck; Boehinger Ingelheim; VBL; Amgen; Kiyatec; Odonate Therapeutics QED; Medefield; Pascal Biosciences; Tocagen; Karyopharm; GW Pharma; Abbvie; VBI; Deciphera; Agios; Genocea; Celgene; Puma; Lilly; BMS; Cortice; Wellcome Trust; Novocure; Novogen; Boston Biomedical; Sunovion; Human Longevity; Insys; ProNai; Pfizer; Notable labs; Medqia Trizel; Medscape, and has contracts with UCLA for the Brain Tumor Program with Oncovir; Merck; Oncoceutics; Novartis; Amgen; Abbvie; DNAtrix; Beigene; BMS; AstraZeneca; Kazia; Agios; Boston Biomedical; Deciphera; Tocagen; Orbus; and Karyopharm. BME is a paid advisor and consultant for Medicenna, MedQIA, Neosoma, Servier Pharmaceuticals, Siemens, Janssen, Imaging Endpoints, Kazia, VBL, Oncoceutics/Chimerix, Sumitomo Dainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Monteris, Global Coalition for Adaptive Research (GCAR), Alpheus Medical, Inc., Curtana Pharma, and Sagimet Biosciences. Grant funding is from Siemens, Servier/Agios, Neosoma, and Janssen.
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained (IRB#14-001261 and #21-000514) from the local ethic committee (University of California Los Angeles).
: Some study subjects or cohorts have been previously reported in:Chakhoyan et al 2018, Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry.
: • prospective• diagnostic or prognostic study• performed at one institution